Hydrochlorothiazide Aurovitas (Hydrochlorothiazide)

Hydrochlorothiazide Aurovitas is indicated for several conditions where reduction of excess fluid or control of blood pressure is needed.

• Treatment of hypertension (high blood pressure).
• Management of edema associated with congestive heart failure.
• Reduction of fluid retention in renal disease such as nephrotic syndrome.
• Relief of ascites and peripheral edema in liver cirrhosis.
• Adjunct therapy for patients requiring additional diuretic effect.

• Hydrochlorothiazide inhibits sodium‑chloride (NaCl) reabsorption in the distal convoluted tubule of the kidney by blocking the NaCl‑Cl⁻ cotransporter. This action increases urinary excretion of sodium, chloride, and water, leading to a reduction in extracellular fluid volume and a consequent decrease in cardiac output and peripheral vascular resistance, which helps lower blood pressure.

Hydrochlorothiazide Aurovitas may cause a range of adverse reactions, some of which are more frequently observed than others.

Common

• Increased frequency of urination.
• Dizziness or light‑headedness, especially when standing.
• Headache.
• Mild electrolyte disturbances such as low potassium (hypokalemia).
• Fatigue or weakness.
• Elevated blood glucose levels.

Serious

• Severe dehydration or electrolyte imbalance (e.g., hyponatremia, hypokalemia).
• Acute gout attacks.
• Pancreatitis.
• Allergic reactions including rash, Stevens‑Johnson syndrome, or anaphylaxis.
• Blood dyscrasias such as leukopenia or thrombocytopenia.

Before starting Hydrochlorothiazide Aurovitas, certain health considerations should be reviewed.

• Assess renal function; use with caution in patients with impaired kidney function.
• Monitor serum electrolytes, especially potassium and sodium, during therapy.
• Patients with a history of gout may experience flare‑ups.
• Caution is advised in diabetic patients as blood glucose may rise.
• Pregnancy category is unknown; avoid use unless clearly needed.
• Elderly individuals may be more susceptible to volume depletion and orthostatic hypotension.
• Document any known sulfonamide allergy, as cross‑reactivity can occur.

Hydrochlorothiazide Aurovitas can interact with several other medications, affecting its safety and efficacy.

Avoid

• Lithium, because thiazides can increase lithium concentrations and risk toxicity.
• Other potent diuretics (e.g., loop diuretics) that may cause excessive fluid loss.
• High‑dose corticosteroids, which can exacerbate electrolyte disturbances.

Use with caution

• Antihypertensive agents (ACE inhibitors, ARBs, beta‑blockers) – may enhance blood‑pressure‑lowering effect.
• Digoxin – risk of hypokalemia‑induced digoxin toxicity.
• Antidiabetic drugs – possible increase in blood glucose requiring dose adjustment.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may reduce diuretic efficacy and affect renal function.
• Alcohol – can increase risk of orthostatic hypotension.